C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment

Diabetes Res Clin Pract. 2012 Dec;98(3):e32-5. doi: 10.1016/j.diabres.2012.09.036. Epub 2012 Oct 13.

Abstract

The amelioration of glucose tolerance by liraglutide was associated with a significant improvement of early insulin-response during OGTT. The serum C-peptide response to glucagon challenge strongly correlated with the improvement of the early insulin-response. The C-peptide response to glucagon challenge would be useful to predict therapeutic response to liraglutide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • C-Peptide / blood*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Dose-Response Relationship, Drug
  • Drug Monitoring
  • Drug Resistance
  • Female
  • Glucagon*
  • Glucagon-Like Peptide 1 / administration & dosage
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / therapeutic use
  • Glucagon-Like Peptide-1 Receptor
  • Glucose Tolerance Test
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / blood
  • Insulin / metabolism*
  • Insulin Secretion
  • Insulin-Secreting Cells / drug effects*
  • Insulin-Secreting Cells / metabolism
  • Kinetics
  • Liraglutide
  • Male
  • Middle Aged
  • Receptors, Glucagon / agonists

Substances

  • C-Peptide
  • GLP1R protein, human
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Insulin
  • Receptors, Glucagon
  • Liraglutide
  • Glucagon-Like Peptide 1
  • Glucagon